Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 154

1.

Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.

Jurczyszyn A, Gozzetti A, Gdula-Argasińska J, Czepiel J, Vij R, Fiala M, Valls DJ, Mądry K, Waszczuk-Gajda A, Grosicki S, Barchnicka A, Crusoe E, Hungria V, Gentile M, Mele G, Ksieniewicz M, Vesole DH, Castillo JJ.

Ann Hematol. 2017 Oct;96(10):1693-1698. doi: 10.1007/s00277-017-3084-9. Epub 2017 Aug 1.

PMID:
28766002
2.

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2.

PMID:
28642620
3.

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series.

Vesole DH, Richter J, Biran N, McBride L, Anand P, Huang M, Kumeli AZ, Klippel Z, Iskander K, Siegel DS.

Leuk Lymphoma. 2018 Jan;59(1):259-261. doi: 10.1080/10428194.2017.1321749. Epub 2017 Jun 5. No abstract available.

PMID:
28583038
4.

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.

Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A.

Cancer. 2017 Aug 15;123(16):3141-3149. doi: 10.1002/cncr.30747. Epub 2017 May 4.

PMID:
28472539
5.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E.

Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Review.

PMID:
28368259
6.

A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.

Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel DS.

Br J Haematol. 2017 Feb;176(3):440-447. doi: 10.1111/bjh.14429. Epub 2016 Nov 18.

PMID:
27859001
7.

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.

Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2017 Jan;23(1):60-66. doi: 10.1016/j.bbmt.2016.10.010. Epub 2016 Oct 24.

PMID:
27789362
8.

Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.

Bilotti E, Vesole DH, McBride L, Schmidt L, Gao Z, Gilani M, McNeill A, Bednarz U, Richter J, Mato A, Graef T, Siegel DS.

Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):558-562. doi: 10.1016/j.clml.2016.08.001. Epub 2016 Aug 10.

PMID:
27769558
9.

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT, Rasche L, Mądry K, Woszczyk D, Raźny M, Usnarska-Zubkiewicz L, Knopińska-Posłuszny W, Wojciechowska M, Guzicka-Kazimierczak R, Joks M, Grosicki S, Ciepłuch H, Rymko M, Vesole DH, Castillo JJ.

Br J Haematol. 2016 Dec;175(5):884-891. doi: 10.1111/bjh.14328. Epub 2016 Sep 29.

PMID:
27682187
10.

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

Biran N, Rowley SD, Vesole DH, Zhang S, Donato ML, Richter J, Skarbnik AP, Pecora A, Siegel DS.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2165-2171. doi: 10.1016/j.bbmt.2016.08.017. Epub 2016 Aug 31.

PMID:
27590107
11.

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.

Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS.

Blood Cancer J. 2016 Sep 2;6(9):e466. doi: 10.1038/bcj.2016.68.

12.

Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.

Baker M, Wang H, Rowley SD, Cai L, Pecora AL, Skarbnik A, Vesole DH, Adler-Brecher B, Kim D, Donato ML.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2047-2055. doi: 10.1016/j.bbmt.2016.08.003. Epub 2016 Aug 10.

13.

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1391-1396. doi: 10.1016/j.bbmt.2016.03.021. Epub 2016 May 7.

14.
15.

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E.

J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.

PMID:
26976420
16.

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ.

Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. Epub 2016 Apr 24.

17.

Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series.

Jurczyszyn A, Olszewska-Szopa M, Vesole AS, Vesole DH, Siegel DS, Richardson PG, Paba-Prada C, Callander NS, Huras H, Skotnicki AB.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):e39-45. doi: 10.1016/j.clml.2015.11.020. Epub 2015 Dec 2. Review.

PMID:
26847816
18.

Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Dhakal B, Vesole DH, Hari PN.

Bone Marrow Transplant. 2016 Apr;51(4):492-500. doi: 10.1038/bmt.2015.325. Epub 2016 Jan 4. Review.

PMID:
26726943
19.

Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.

Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M, Leleu X, Rasche L, Nooka AK, Druzd-Sitek A, Walewski J, Davila J, Caers J, Maisnar V, Gertz M, Gentile M, Fantl D, Mele G, Vesole DH, Yee AJ, Shustik C, Lentzsch S, Zweegman S, Gozzetti A, Skotnicki AB, Castillo JJ.

Leuk Lymphoma. 2016 Sep;57(9):2071-6. doi: 10.3109/10428194.2015.1128542. Epub 2016 Jan 4.

PMID:
26726867
20.

Counterpoints: Do patients with multiple myeloma need maintenance treatment? No, maintenance treatment should not be used outside clinical trials.

Vesole DH, Siegel DS.

Clin Adv Hematol Oncol. 2015 Mar;13(3):163, 167-9. No abstract available.

PMID:
26352424

Supplemental Content

Loading ...
Support Center